BBlogFlow

Every Story is Unique, Every Journey Matters - UN Africa Renewal

·5d ago
Source: UN Africa Renewal
Read the original article

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

The World Health Organization has been supporting Kenya's Ministry of Health to implement the Women's Integrated Cancer Screening (WICS) program. Across Africa, too many women are dying prematurely from breast and cervical cancers. In 2024 alone, 350,000 women across the continent died from these diseases, often because prevention, early detection, diagnosis and treatment came too late, or were inaccessible. Behind every statistic is a woman, a family and a community. A mother waiting too long for a diagnosis. A daughter unable to access preventive care. A family struggling to afford treatment. These stories are unique but the responsibility before us is shared. Our message to governments, policymakers and partners is clear: the time has come to accelerate action on women’s cancers and move them from the margins of health policy to the centre of Africa’s health, development and financing agendas. The African Union is leading the way by placing the health and wellbeing of Africa’s people at the heart of the continent’s development agenda.

This article is an excerpt. To read the full content, visit the original source. UN Africa Renewal

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Medical Xpress·

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·